Imagen de Portada

Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
por: Lasin Ozbek, et al.
Publicado: (2026)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
por: Rayanne Santos de Paulo, et al.
Publicado: (2026)

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
por: Giorgia Rutigliani, et al.
Publicado: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
por: Roberta Scairati, et al.
Publicado: (2026)

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
por: Binayak Sinha, et al.
Publicado: (2025)

Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review
por: Jorge Urbina, et al.
Publicado: (2026)

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
por: Joachim Holt, et al.
Publicado: (2025)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
por: Inyoung Hwang, et al.
Publicado: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
por: Cynthia F. X. C. A. Silva, et al.
Publicado: (2026)

GLP‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation
por: Hao Dai, et al.
Publicado: (2025)

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials
por: Lucas Sabatella, et al.
Publicado: (2025)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
por: Matheus Souza, et al.
Publicado: (2026)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
por: Jirawan Vienghirun, et al.
Publicado: (2026)

Interrupting prolonged sitting reduces postprandial GIP but not GLP ‐1 responses in type 2 diabetes
por: Beth K. Logan, et al.
Publicado: (2025)

Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals
por: Liva S. L. Krogh, et al.
Publicado: (2026)

ObesityWeek ® 2025—Reflecting on an Exciting Time in Obesity Research and Treatment
por: Susan Z. Yanovski, et al.
Publicado: (2026)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
por: Haisheng Wu, et al.
Publicado: (2026)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
por: Tahmid Hussain, et al.
Publicado: (2026)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
por: W. Timothy Garvey, et al.
Publicado: (2024)

GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
por: Hiba Jebeile, et al.
Publicado: (2025)

Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
por: Michael Lim, et al.
Publicado: (2026)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
por: Yazan Alhamdan, et al.
Publicado: (2026)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
por: Muhammad Tahir, et al.
Publicado: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists: Considerations for Treating Preconception Obesity
por: Lauren T. Berube, et al.
Publicado: (2026)

GLP ‐1, GIP , and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids
por: Carlijn A. Hoekx, et al.
Publicado: (2026)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
por: Shio‐Shin Jean, et al.
Publicado: (2026)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
por: Hans Johnson, et al.
Publicado: (2025)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Publicado: (2026)

Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study
por: Liva S. L. Krogh, et al.
Publicado: (2025)

Cardiometabolic Profiles and Treatment Trajectories of GLP ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland
por: Klaudia Nowak, et al.
Publicado: (2026)

Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study
por: Julia Lischka, et al.
Publicado: (2026)

Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
por: Theresa Hunter Gibble, et al.
Publicado: (2025)

Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
por: Jesús Argente, et al.
Publicado: (2026)

Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study
por: Leslie J. Heinberg, et al.
Publicado: (2025)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
por: Hezekiah C. T. Au, et al.
Publicado: (2026)

Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learning–Based Analysis of a Large Real World Cohort
por: Pierpaolo Falcetta, et al.
Publicado: (2026)

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults
por: Jie‐Syuan Wu, et al.
Publicado: (2026)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes
por: Ying Lu, et al.
Publicado: (2025)

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study
por: Yuxin Fan, et al.
Publicado: (2025)

Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”
Publicado: (2026)